BIOTRONIK Blog

The Multicenter Study Will Evaluate the ElePulse™ PFA System in Patients with Symptomatic, Drug-Refractory Paroxysmal Atrial Fibrillation ElePulse Introduces a True Single-Shot, Single-Position Approach BIOTRONIK today announced the enrollment of the first patient in the RESET  AF 3D Study, a clinical study to evaluate the ElePulse™ Pulsed Field Ablation (PFA) System for performance in patients in the treatment of atrial fibrillation (AF). The study aims to support CE Mark approval for the ElePulse PFA System, which introduces a single-shot, single-position approach to pulmonary vein isolation

This Three-Year Collaboration Aims to Deliver Scalable Health Solutions for Improved Disease Management The Initiative Hopes to Benefit Patients Particularly in Remote or Underserved Regions with Limited Access to Care BIOTRONIK, a global leader in medical technology, and the University of Sydney, one of the world’s top research and teaching institutions, have signed a Memorandum of Understanding (MoU) to jointly advance digital and connected health innovations through 2028. By combining BIOTRONIK’s expertise in implanted cardiac devices and remote monitoring with the University of Sydney’s

BIOTRONIK today announced the successful first-in-human implantation of a device from its new Acticor/Rivacor Sky ICD/CRT-D devices, specifically engineered to support conduction system pacing via left bundle branch area pacing (LBBAP). This emerging technique provides a more physiological activation of cardiac tissue for patients requiring ventricular pacing. The first system has been implanted at the Gold Coast University Hospital in Queensland, Australia by Cardiac Electrophyisologist Dr. Robert Park. This implantation took place as part of the First-in-Human (FIH) study, involving